Argenx stock: Argenx gains 5.41 percent in the session

Published on 10/20/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ALKIVIA beat placebo by 15.40 points at 52 weeks. Argenx stock costs EUR 769.30 on October 20, 2026, up 5.41 percent versus the Euronext close.

Clinical data and trading move

argenx reported a 15.40-point ALKIVIA benefit at 52 weeks on October 19, 2026.
argenx will discuss third-quarter 2026 results on October 22, 2026.
argenx stock costs EUR 769.30 at Lang & Schwarz on October 20, 2026 at 4:07 p.m. CEST, 5.41 percent above the Euronext close of October 19, 2026.

Architekturaufnahme eines modernen Biotechnologie-Campus in Belgien, Glas-Stahl-Gebäude mit Dachgärten, Radfahrer auf baumgesäumter Allee, nordeeuropäischer Himmel — Argenx NL0010832176 moderner belgischer Biotech-Campus mit Glasfassaden und Radfahrern unter bewölktem Herbsthimmel, Illustration mit AI erstellt.

argenx SE (ISIN NL0010832176) reported a 15.40-point treatment advantage for efgartigimod in the ALKIVIA phase 3 study at 52 weeks on October 19, 2026. According to Ideal Investor, the combined immune-mediated necrotizing myopathy and dermatomyositis population reached an average Total Improvement Score of 47.95, versus 32.56 for placebo. The stock was trading at EUR 769.30 at Lang & Schwarz on October 20, 2026 at 4:07 p.m. CEST, up 5.41 percent versus the Euronext close of October 19, 2026 at EUR 729.80.

ALKIVIA adds a quantified trial signal

The clinical result gives investors a concrete measure for the program: 47.95 points for treated patients compared with 32.56 points for placebo. The 15.40-point difference was reported with a p-value of 0.0011, while the study included 175 treated patients in its phase 3 portion, according to Ideal Investor. The data are scheduled for a late-breaking oral presentation at the ACR Convergence congress on November 11, 2026.

Trading moves ahead of results

The Lang & Schwarz price stands EUR 39.50 above the Euronext close of EUR 729.80, a gain of 5.41 percent. The quoted price remains below the USD 1,072.75 52-week high and above the USD 661.85 52-week low recorded in the primary-market quote, while the USD 54.5 billion market capitalization gives the move a sizeable valuation backdrop.

October 22 is the next date

argenx will discuss its third-quarter 2026 financial results and provide a business update on October 22, 2026, with the webcast scheduled for 2:30 p.m. CET. The date was announced on October 15, 2026 in a release carried by Yahoo Finance. Historical first-half 2026 figures cited by Markets Insider put revenue at USD 2.82 billion and net profit at USD 838.82 million for the quarter ending June 30, 2026.

argenx enters the next catalyst

The immediate market frame combines a 5.41 percent session increase with a clinical result that carries a dated numerical endpoint. The October 22 update will give investors the next scheduled checkpoint for revenue, earnings and the wider immunology pipeline.

The stock was trading at EUR 769.30 at Lang & Schwarz on October 20, 2026 at 4:07 p.m. CEST, 5.41 percent above the Euronext close of October 19, 2026 at EUR 729.80. The further course of trading is shown by the continuously updated real-time quote of argenx stock.